Maria Sromek1, Maciej Glogowski2, Magdalena Chechlinska1, Mariusz Kulinczak1, Lukasz Szafron3, Klara Zakrzewska3, Joanna Owczarek3, Piotr Wisniewski3, Robert Wlodarczyk2, Lukasz Talarek2, Maciej Turski2, Jan Konrad Siwicki4. 1. Department of Immunology, Maria Sklodowska-Curie Institute - Oncology Centre, Roentgen 5, 02-781, Warsaw, Poland. 2. Department of Lung Cancer and Chest Tumors, Maria Sklodowska-Curie Institute - Oncology Centre, Roentgen 5, 02-781, Warsaw, Poland. 3. Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Centre, Roentgen 5, 02-781, Warsaw, Poland. 4. Department of Immunology, Maria Sklodowska-Curie Institute - Oncology Centre, Roentgen 5, 02-781, Warsaw, Poland. jan.siwicki@coi.pl.
Abstract
PURPOSE: The majority of non-small cell lung cancer (NSCLC) patients presents with an advanced-stage disease and, consequently, exhibits a poor overall survival rate. We aimed to assess changes in plasma miR-9, miR-16, miR-205 and miR-486 levels and their potential as biomarkers for the diagnosis and monitoring of NSCLC patients. METHODS: Plasma was collected from 50 healthy donors and from NSCLC patients before surgery (n = 61), 1 month after surgery (n = 37) and 1 year after surgery (n = 14). microRNA levels were quantified using qRT-PCR. RESULTS: We found in NSCLC patients before treatment, both with squamous cell carcinoma (SQCC) and adenocarcinoma (ADC), significantly higher plasma miR-16 and miR-486 levels than in healthy individuals. Pre-treatment miR-205 concentrations were found to be significantly higher in SQCC than in ADC patients, and only SQCC patients presented significantly higher circulating miR-205 levels than healthy donors. SQCC plasma miR-9 levels were not different from normal control levels, but in ADC they were found to be significantly decreased. A combination of plasma miR-16, miR-205 and miR-486 measurements was found to discriminate NSCLC patients from healthy persons, with a specificity of 95% and a sensitivity of 80%. Following tumor resection, we found that the miR-9 and miR-205 levels significantly decreased, even below the normal level, whereas the increased miR-486 level persisted up to one year after surgery, and the miR-16 level decreased to normal. After tumor resection, none of the miR levels tested was found to relate to recurrence. CONCLUSIONS: Our data indicate that miR-9, miR-16, miR-205 and miR-486 may serve as NSCLC biomarkers. The observed cancer-related pre- and post-operative changes in their plasma levels may not only reflect the presence of a primary cancer, but also of a systemic response to cancer.
PURPOSE: The majority of non-small cell lung cancer (NSCLC) patients presents with an advanced-stage disease and, consequently, exhibits a poor overall survival rate. We aimed to assess changes in plasma miR-9, miR-16, miR-205 and miR-486 levels and their potential as biomarkers for the diagnosis and monitoring of NSCLCpatients. METHODS: Plasma was collected from 50 healthy donors and from NSCLCpatients before surgery (n = 61), 1 month after surgery (n = 37) and 1 year after surgery (n = 14). microRNA levels were quantified using qRT-PCR. RESULTS: We found in NSCLCpatients before treatment, both with squamous cell carcinoma (SQCC) and adenocarcinoma (ADC), significantly higher plasma miR-16 and miR-486 levels than in healthy individuals. Pre-treatment miR-205 concentrations were found to be significantly higher in SQCC than in ADC patients, and only SQCC patients presented significantly higher circulating miR-205 levels than healthy donors. SQCC plasma miR-9 levels were not different from normal control levels, but in ADC they were found to be significantly decreased. A combination of plasma miR-16, miR-205 and miR-486 measurements was found to discriminate NSCLCpatients from healthy persons, with a specificity of 95% and a sensitivity of 80%. Following tumor resection, we found that the miR-9 and miR-205 levels significantly decreased, even below the normal level, whereas the increased miR-486 level persisted up to one year after surgery, and the miR-16 level decreased to normal. After tumor resection, none of the miR levels tested was found to relate to recurrence. CONCLUSIONS: Our data indicate that miR-9, miR-16, miR-205 and miR-486 may serve as NSCLC biomarkers. The observed cancer-related pre- and post-operative changes in their plasma levels may not only reflect the presence of a primary cancer, but also of a systemic response to cancer.
Entities:
Keywords:
Cancer biomarker; Circulating microRNA; Non-small cell lung carcinoma
Authors: Lynette M Sholl; Dara L Aisner; Timothy Craig Allen; Mary Beth Beasley; Philip T Cagle; Vera L Capelozzi; Sanja Dacic; Lida P Hariri; Keith M Kerr; Sylvie Lantuejoul; Mari Mino-Kenudson; Kirtee Raparia; Natasha Rekhtman; Sinchita Roy-Chowdhuri; Eric Thunnissen; Ming Tsao; Marina Vivero; Yasushi Yatabe Journal: Arch Pathol Lab Med Date: 2016-05-19 Impact factor: 5.534
Authors: Dragan Subotic; Dragan Mandaric; Gordana Radosavljevic; Jelena Stojsic; Milan Gajic Journal: Ann Thorac Med Date: 2009-04 Impact factor: 2.219
Authors: Charalambos C Solomides; Barry J Evans; Jean-Marc Navenot; Rajanikanth Vadigepalli; Stephen C Peiper; Zi-xuan Wang Journal: Acta Cytol Date: 2012-11-24 Impact factor: 2.319
Authors: Vasily N Aushev; Irina B Zborovskaya; Konstantin K Laktionov; Nicolas Girard; Marie-Pierre Cros; Zdenko Herceg; Vladimir Krutovskikh Journal: PLoS One Date: 2013-10-09 Impact factor: 3.240
Authors: Martina Faraldi; Laura Gerosa; Marta Gomarasca; Veronica Sansoni; Silvia Perego; Ewa Ziemann; Giuseppe Banfi; Giovanni Lombardi Journal: Diagnostics (Basel) Date: 2021-04-30